Main Menu
Untitled Page
Home > Equity > Company info > Company Snapshot
18 October 2017

Search Quotes

  Enter at least 3 characters from BSE Code for a company or the company's name

Aurobindo Pharma Ltd (Pharmaceuticals - Indian - Bulk Drugs & Formln)

Last Price 756.00
Net Changes -8.45
Volume 1212700
Prev Close 764.45
756.00 -8.45 (-1.11%)
Date: Oct 18,2017 EOD




Index Details Pharmaceuticals - Indian - Bulk Drugs & Formln


Chart

Stock Price Details

Market Statistics

Open Price 768 Div Yield (%) 0.42
Buy (Size) 0.00(×0) Eps(Rs) 27.7
Sell (Size) 0.00(×0) Book Value(Rs) 143.9909803
Buy Quantity 0 Market Cap(Rs.Cr) 44365.95
Sell Quantity 0 Face Value(Rs) 1
Today's High 768 Market Lot 1
Today's Low 753.8 AGM Date Aug
52-Week High 844 Book Closure Date Aug
52-Week Low 504 ISIN No. INE406A01037

Share Holding Pattern

  No Of shares % Share Holding
Total Foreign (Promoter & Group) 18000000 3.07
Indian (Promoter & Group) 285925934 48.80
Total of Promoter 303925934 51.87
Non Promoter (Institution) 200056312 34.15
Non Promoter (Non-Institution) 81900163 13.98
Total Non Promoter 281956475 48.13
Total Promoter & Non Promoter 585882409 100.00
Custodians(Against Depository Receipts) 0 0.00
Grand Total 585882409 100.00

Company News

17-Oct-2017  Aurobindo Pharma receives final approval for Esomeprazole Magn...
Aurobindo Pharma receives final approval for Esomeprazole Magnesium Delayed-Release Capsules

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture Esomeprazole Magnesium Delayed-Release Capsules OTC, 20mg. Esomeprazole Magnesium Delayed-Release Capsules OTC, a therapeutic equivalent generic version of AstraZeneca's Nexium® 24HR Capsules. The product will be launched immediately.

Nexium® 24HR (Esomeprazole Magnesium) capsules are indicated to treat frequent heartburn (occurs 2 or more days a week). The approved product has an approximate annual sales in excess of US$ 300 million, according to IRI database.

This is the 127th ANDA (including 23 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India used for manufacturing oral products. Aurobindo now has a total of 335 ANDA approvals (296 Final approvals including 16 from Aurolife Pharma LLC and 39 tentative approvals) from USFDA.

17-Oct-2017  Aurobindo Pharma gets healthier after USFDA nod for drug
Aurobindo Pharma gets healthier after USFDA nod for drug

The announcement was made during market hours today, 17 October 2017.

Meanwhile, the S&P BSE Sensex was up 21.28 points or 0.07% at 32,654.92.

On the BSE, 61,722 shares were traded on the counter so far as against the average daily volumes of 2.38 lakh shares in the past one quarter. The stock had hit a high of Rs 771.75 and a low of Rs 753.15 so far during the day. The stock had hit a 52-week high of Rs 844 on 19 October 2016 and a 52-week low of Rs 504 on 29 May 2017.

The stock has gained 5.08% in four sessions to its ruling price, from its close of Rs 732.15 on 11 October 2017.

The stock had underperformed the market over the past one month till 16 October 2017, falling 0.11% compared with the Sensex's 1.12% gains. The stock had also underperformed the market over the past one quarter, gaining 1.59% as against the Sensex's 1.91% rise. The scrip had also underperformed the market over the past one year, dropping 8.04% as against the Sensex's 17.92% rise.

The large-cap company has equity capital of Rs 58.59 crore. Face value per share is Re 1.

Aurobindo Pharma announced that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture Esomeprazole Magnesium Delayed-Release Capsules OTC, 20mg.

Esomeprazole Magnesium Delayed-Release Capsules OTC is a therapeutic equivalent generic version of AstraZeneca's Nexium 24HR Capsules. The product will be launched immediately.

Nexium 24HR (Esomeprazole Magnesium) capsules are indicated to treat frequent heartburn - occuring 2 or more days a week. The approved product has an approximate annual sales in excess of $300 million, according to IRI database.

This is the 127th abbreviated new drug application (ANDA), including 23 tentative approvals to be approved out of unit VII formulation facility in Hyderabad, India used for manufacturing oral products. Aurobindo now has a total of 335 ANDA approvals (296 final approvals including 16 from Aurolife Pharma LLC and 39 tentative approvals) from USFDA.

Aurobindo Pharma's consolidated net profit fell 11.4% to Rs 518.51 crore on 2.3% decline in net sales to Rs 3621.07 crore in Q1 June 2017 over Q1 June 2016.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients.

17-Oct-2017  Aurobindo Pharma Limited - Press Release
Aurobindo Pharma Limited - Press Release

Aurobindo Pharma Limited has informed the Exchange regarding a press release dated October 17, 2017, titled 'Aurobindo Pharma receives USFDA Approval for Esomeprazole Magnesium DR Capsules OTC'.
25-Sep-2017  Other announcement of Aurobindo Pharma Ltd.
Other announcement of Aurobindo Pharma Ltd.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herewith enclose notice issued for the attention of equity shareholders of the Company on 18.09.2017 which was published on 23.09.2017, intimating that the equity shares in respect of which dividend remain unclaimed for seven consecutive years, would be transferred to Investor Education and Protection Fund (IEPF), in the following newspapers. Business Standard (English daily) Andhra Prabha (Telugu daily).
21-Sep-2017  Aurobindo Pharma Limited - Analysts/Institutional Investor Mee...
Aurobindo Pharma Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Aurobindo Pharma Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates
05-Sep-2017  Aurobindo Pharma Limited - Analysts/Institutional Investor Mee...
Aurobindo Pharma Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Aurobindo Pharma Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates
01-Sep-2017  Other announcement of Aurobindo Pharma Ltd.
Other announcement of Aurobindo Pharma Ltd.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the shareholders of the Company at the 30th Annual General Meeting (AGM) held on August 31, 2017 have appointed B S R & Associates LLP, Chartered Accountants (Firm Registration No.116231W / W-100024) as the Statutory Auditors of the Company. A brief profile of B S R & Associates LLP is enclosed.
01-Sep-2017  Aurobindo Pharma Limited - Change in Auditors
Aurobindo Pharma Limited - Change in Auditors

Aurobindo Pharma Limited has informed the Exchange regarding Change in Auditors of the company.
01-Sep-2017  Aurobindo Pharma Limited - Shareholders meeting
Aurobindo Pharma Limited - Shareholders meeting

Aurobindo Pharma Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 31, 2017. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.
24-Aug-2017  Other announcement of Aurobindo Pharma Ltd.
Other announcement of Aurobindo Pharma Ltd.

Please refer to our letter dated 5th August 2017 wherein we have intimated the schedule of Investors/Analysts call on 10th August 2017. In this connection, we would like to inform you that the Transcript of the Q1 FY 2017-18 earnings conference call of 10th August, 2017 has been uploaded on the website of the Company and is available in the following web link: http://www.aurobindo.com/docs/financial-results/2017-2018/aurobindo-pharma- q1-fy-18-earnings-call-transcript.pdf
Incorporation Year 1986 
Registered Office Plot No 2 Maitrivihar,Behind Maithri Vanam Ameerpet,
Hyderabad,
Telangana-500038
Telephone 91-40-23736370 
Fax 91-40-23747340 
Chairman K Ragunathan
Managing Director N Govindarajan
Company Secretary B Adi Reddy 
Auditor S R Batliboi & Associates LLP 
Face Value(Rs)
Market Lot
Listing MCX-SX,BSE,NSE 
Registrar Karvy Computershare Pvt Ltd
Karvy Selenium Tow-B,Pl-31&32 Gachibowli,Nanakramguda,Hyderabad-500032 
Toll Free number: 1800-425-5501 / 1800-103-5501
FINANCIAL TOOLS